Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 6, 1999, Pages 1500-1502

  Chou, Sunwen ^a   Lurain, Nell S ^b   Weinberg, Adriana ^c   Cai, Guang Yung ^c   Sharma, Prem L ^d   Crumpacker, Clyde S ^d  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GENE DELETION; GENE INSERTION; GENETIC RESISTANCE; GENETIC VARIABILITY; HUMAN CYTOMEGALOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; VIRUS GENE; VIRUS STRAIN;

EID: 0033063981     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.6.1500     Document Type: Article

References (14)

1. Anders, D. G., and L. A. McCue. 1996. The human cytomegalovirus genes and proteins required for DNA synthesis. Intervirology 39:378-388.
2. Baldanti, F., M. R. Underwood, S. C. Stanat, K. K. Biron, S. Chou, A. Sarasini, E. Silini, and G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395.
3. Chou, S., and K. M. Dennison. 1991. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis. 163:1229-1234.
4. Chou, S., S. Guentzel, K. R. Michels, R. C. Miner, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239-242.
5. Chou, S., G. Marousek, S. Guentzel, et al. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:785-789.
6. Chou, S., G. Marousek, D. M. Parenti, et al. 1998. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J. Infect. Dis. 178:526-530.
7. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936.
8. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
9. Crumpacker, C. S. (ed.). 1996. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12(Suppl. 1):S1-S22.
10. Drew, W. L., R. Miner, and E. Saleh. 1993. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin. Diagn. Virol. 1:179-185.
11. Erice, A., C. Gil-Roda, J. L. Perez, et al. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immuno-compromised patients. J. Infect. Dis. 175:1087-1092.
12. Lurain, N. S., K. D. Thompson, E. W. Holmes, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7145-7152.
13. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
14. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.